Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CODX 
Co-Diagnostics Inc (CODX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: CODX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.99% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.43M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 2 | Beta 0.58 | 52 Weeks Range 0.23 - 2.23 | Updated Date 07/12/2025 |
52 Weeks Range 0.23 - 2.23 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -17009.68% |
Management Effectiveness
Return on Assets (TTM) -33.82% | Return on Equity (TTM) -56.8% |
Valuation
Trailing PE - | Forward PE 16 | Enterprise Value -11119641 | Price to Sales(TTM) 2.41 |
Enterprise Value -11119641 | Price to Sales(TTM) 2.41 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 33712500 | Shares Floating 31078907 |
Shares Outstanding 33712500 | Shares Floating 31078907 | ||
Percent Insiders 9 | Percent Institutions 17.44 |
Upturn AI SWOT
Co-Diagnostics Inc
Company Overview
History and Background
Co-Diagnostics, Inc. was founded in 2013. It focuses on developing and manufacturing molecular diagnostic solutions, primarily for infectious diseases.
Core Business Areas
- Molecular Diagnostics: Develops and sells real-time polymerase chain reaction (PCR) tests for detecting various pathogens, including infectious diseases.
Leadership and Structure
Dwight Egan is the CEO. The company operates with a typical corporate structure with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Logix Smart COVID-19 Test: A PCR test for detecting SARS-CoV-2. While market share varies, it gained significant traction during the pandemic. Competition includes Roche (RHHBY), Abbott (ABT), and Thermo Fisher Scientific (TMO).
Market Dynamics
Industry Overview
The molecular diagnostics market is growing due to increasing demand for rapid and accurate disease detection.
Positioning
Co-Diagnostics is a smaller player in the market, focusing on cost-effective and accessible diagnostic solutions. Its competitive advantage lies in its CoPrimer technology.
Total Addressable Market (TAM)
The global molecular diagnostics market is estimated to be worth billions of USD. Co-Diagnostics is positioned to capture a portion of this TAM through its specialized diagnostic solutions.
Upturn SWOT Analysis
Strengths
- CoPrimer technology
- Rapid test development
- Cost-effective solutions
Weaknesses
- Smaller market presence compared to major players
- Reliance on specific product lines
- Geographic concentration of sales
Opportunities
- Expanding product portfolio
- Entering new geographic markets
- Partnerships and collaborations
Threats
- Intense competition
- Regulatory changes
- Fluctuations in demand for specific tests
Competitors and Market Share
Key Competitors
- RHHBY
- ABT
- TMO
Competitive Landscape
Co-Diagnostics faces significant competition from larger, more established players. Its CoPrimer technology offers a competitive advantage, but it needs to expand its market presence.
Growth Trajectory and Initiatives
Historical Growth: Growth has been largely tied to the demand for COVID-19 testing.
Future Projections: Future growth will depend on the company's ability to diversify its product line and expand into new markets.
Recent Initiatives: Focus on developing new diagnostic tests and expanding international distribution.
Summary
Co-Diagnostics is a molecular diagnostics company with a focus on infectious disease testing. The company's success is largely tied to the demand for its COVID-19 tests. Future growth depends on diversification and expansion into new markets, as it faces strong competition from larger companies. The company needs to broaden its assay offerings to increase revenues outside of COVID related diagnostics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Co-Diagnostics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2017-07-12 | Chairman & CEO Mr. Dwight H. Egan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 132 | Website https://co-dx.com |
Full time employees 132 | Website https://co-dx.com | ||
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.